Get started
Author

Giulia Gallusi

Observed name: G. Gallusi
OpenAlex ID: A5061172302
Prognostic ability of BCLC-B Subclassification in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
2017 · Marco Biolato, Giulia Gallusi, et al. · Annals of Hepatology · 34
PDF
Type 3 hereditary hemochromatosis in a patient from sub-Saharan Africa: Is there a link between African iron overload and TFR2 dysfunction?
2012 · Silvia Majore, Bianca Maria Ricerca, et al. · Blood Cells Molecules and Diseases · 11
Diagnostic imaging for hepatocellular carcinoma
2019 · Adriano De Santis, Giulia Gallusi · Hepatoma Research · 10
PDF
The macrophage migration inhibitory factor −173G/C polymorphism is not significantly associated with necrotizing enterocolitis in preterm infants
2013 · Giusi Prencipe, Cinzia Auriti, et al. · Journal of Pediatric Surgery · 6
Treatment of PPI-resistant gastro-oesophageal reflux: A systematic review
2018 · Giulia Gallusi, Stefano Pontone · Arab Journal of Gastroenterology · 4
Endoscopic Surveillance at 3 Months Post EMR for Early Detection of RRA
2018 · C. Quondamcarlo, G. Gallusi, et al. · EC Gastroenterology and Digestive System
Prediction of post-operative liver failure in cirrhotic patients undergoing surgical resection for hepatocellular carcinoma: The role of liver stiffness measured by acoustic radiation force impulse and the proposal for a new mathematical model score
2016 · C. Iegri, A. De Santis, et al. · Digestive and Liver Disease
Prediction of Post-Operative Liver Failure in Cirrhotics Undergoing Surgical Resection for Hepatocellular Carcinoma: The Role of Liver Stiffness Measured by Acoustic Radiation Force Impulse andthe Proposal for a New Mathematical Model Score
2016 · C. Iegri, A. De Santis, et al. · Journal of Hepatology
Prognostic Validation of Proposed BCLC-B Substaging System in Hepatocellular Carcinoma Patients Treated by Transarterial Chemoembolization
2016 · M. Biolato, G. Gallusi, et al. · Journal of Hepatology
Clinically guided adjustment of sorafenib daily dose is advisable for cirrhotics patients with hepatocellular carcinoma (HCC)
2015 · G. Gallusi, A. De Santis, et al. · Digestive and Liver Disease
P1029 Liver Stiffness (ls) Assessed With Acoustic Radiation Force Impulse (arfi) Can Be Prognostic for First Episode of Ascites (ad) in Patients Affected by Chronic Liver Disease (cld)
2014 · A. De Santis, C. Bassanelli, et al. · Journal of Hepatology
T-42 Can adipose tissue delay the onset of dose limiting toxicity in patients with HCC during sorafenib treatment?
2013 · A. De Santis, C. Iegri, et al. · Digestive and Liver Disease
PDF
F-38 Chubby is beautiful: subcutaneous fat area as predictor of better survival in patients with HCC treated with sorafenib
2013 · A. De Santis, C. Iegri, et al. · Digestive and Liver Disease
PDF
F-24 Acoustic radiation force impluse (ARFI) vs. Fibroscan (FS) in detection of severe fibrosis in ortotopic liver transplant: preliminary results
2013 · A. De Santis, C. Bassanelli, et al. · Digestive and Liver Disease
PDF
1009 Is Skin Toxicity a Predictor of Better Survival of Patients With Hcc Treated With Sorafenib?
2012 · A. De Santis, C. Iegri, et al. · Journal of Hepatology
P.08.7 Major Bleeding Episodes Among Patients With Hcc During Sorafenib Treatment: the Dark Side of a Relatively Safe Drug?
2012 · A. De Santis, C. Iegri, et al. · Digestive and Liver Disease
P.08.19 Is Skin Toxicity a Predictor of Better Survival of Patients With Hcc Treated With Sorafenib?
2012 · A. De Santis, C. Iegri, et al. · Digestive and Liver Disease
T-41 Major bleeding episodes among patients with HCC during sorafenib treatment: the dark side of a relatively safe drug?
2012 · A. De Santis, C. Iegri, et al. · Digestive and Liver Disease
T-46 Is skin toxicity a predictor of better survival of patients with HCC treated with sorafenib?
2012 · A. De Santis, C. Iegri, et al. · Digestive and Liver Disease
Works count: 21
Citation count: 65
H-index: 4
I10-index: 3
Year
Topic
Type